Tissue adhesive

Claim 2

A tissue adhesive comprising plasma proteins of human or animal origin, which plasma proteins contain: factor XIII in an amount of at least 7 units/ml, fibrinogen in an amount of at least 70 mg/ml, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounting to at least 100; cold-insoluble globulin and albumin, the ratio of fibrinogen to cold-insoluble globulin to albumin being 60 to 98:0.5 to 20:0 to 15; plasminogen-activator inhibitor or plasmin inhibitor in an amount of 20 to 2,000 KIU per ml, wherein the tissue adhesive as determined according to the SDS-polyacrylamide-gel-electrophoresis method is capable of complete cross-linking of the fibrin-γ-chains after 3 to 5 minutes of incubation and of at least 35% cross-linking of the fibrin-α-chains after two hours of incubation.

Claim 3

A method of producing a tissue adhesive as described in claim 1, which comprises: (a) thawing deepfrozen fresh plasma to obtain a cryoprecipitate and a soluble plasma protein; (b) separating the cryoprecipitate from the soluble plasma protein; (c) washing the thus obtained cryoprecipitate at about 2° C. with a buffer solution having a pH of about 6.5 and containing sodium citrate, sodium chloride, glycine, glucose and a plasminogen-activator inhibitor or a plasmin inhibitor; (d) heating the washed precipitate to about 37° C. to obtain a liquid tissue adhesive; and (e) deepfreezing the liquid tissue adhesive until ready to use.

Claim 4

A method of producing a tissue adhesive as described in claim 1, which comprises the steps of: (a) thawing deepfrozen fresh plasma to obtain a cryoprecipitate and soluble plasma protein; (b) separating the cryoprecipitate from the soluble plasma protein; (c) washing the thus obtained cryoprecipitate at about 2° C. with a buffer solution having a pH of about 6.5 and containing sodium citrate, sodium chloride, glycine and glucose; (d) heating the washed precipitate to about 37° C. to obtain a liquid tissue adhesive; (e) adding a plasminogen-activator inhibitor or a plasmin inhibitor and (f) deepfreezing the liquid tissue adhesive until ready to use.

Claim 5

A method of tissue or organ adhesion in mammals which comprises applying onto the organ or tissue an amount sufficient to function as an adhesive of the adhesive as described in claim 1 and a mixture of thrombin and calcium chloride.

Claim 6

The method as described in claim 4, wherein the mixture of thrombin and calcium chloride is added to the adhesive prior to applying the tissue adhesive to the tissue or organ.

Claim 7

A tissue adhesive comprising plasma proteins of human or animal origin, which plasma proteins contain: factor XIII in an amount of at least 7 units/ml, fibrinogen in an amount of at least 70 mg/ml, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounting to at least 100; cold-insoluble globulin and albumin, the ratio of fibrinogen to cold-insoluble globulin to albumin being 60 to 98:0.5 to 20:0 to 15; plasminogen-activator-inhibitor or plasmin inhibitor selected from the group consisting of C1-inactivator, α 2 -antiplasmin, α 2 -macroglobulin, α 1 -antitrypsin, epsilonaminocaproic acid and tranexamic acid, the concentration being such that fibrinolysis is prevented, wherein the tissue adhesive as determined according to the SDS-polyacrylamide-gel-electrophoresis method is capable of complete cross-linking of the fibrin-γ-chains after 3 to 5 minutes of incubation and of at least 35% cross-linking of the fibrin-α-chains after two hours of incubation.

Claim 8

A tissue adhesive comprising plasma proteins of human or animal origin, which plasma proteins contain: factor XIII in an amount of at least 7 units/ml, fibrinogen in an amount of at least 70 mg/ml, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounting to at least 100; cold-insoluble globulin and albumin, the ratio of fibrinogen to cold-insoluble globulin to albumin being 60 to 98:0.5 to 20:0 to 15; plasminogen-activator-inhibitor or plasmin inhibitor selected from the group consisting of C1-inactivator, α 2 -antiplasmin, α 2 -macroglobulin, α 1 -antitrypsin, epsilonaminocaproic acid and tranexamic acid, the concentration being such that fibrinolysis is prevented, wherein the tissue adhesive as determined according to the SDS-polyacrylamide-gel-electrophoresis method is capable of complete cross-linking of the fibrin-γ-chains after 3 to 5 minutes of incubation and of at least 35% cross-linking of the fibrin-α-chains after two hours of incubation.

Claim 9

A tissue adhesive as described in claim 6 wherein C1-inactivator in an amount of 0.1 to 75 U/ml is used.

Claim 10

A tissue adhesive as described in claim 2 wherein α 2 -antiplasmin in an amount of 0.05 to 80 U/ml is used.

Claim 11

A tissue adhesive as described in claim 6 wherein α 2 -macroglobulin in an amount of 0.5 to 90 mg/ml is used.

Claim 12

A tissue adhesive as described in claim 6 wherein α 1 -antitrypsin in an amount of 0.5 to 90 mg/ml is used.

Claim 13

A tissue adhesive as described in claim 6 wherein epsilon-aminocaproic acid in an amount of 1 to 500 mg/ml is used.

Claim 14

A tissue adhesive as described in claim 6 wherein tranexamic acid in an amount of 1 to 300 mg/ml is used.